3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
8
Prostatic Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Cardiotoxicity
3
Triple Negative Breast Neoplasms
2
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Heart Failure
2
Glioblastoma
2
Endometrial Neoplasms
2
Endometrial Hyperplasia
2
Waldenstrom Macroglobulinemia
1
Rectal Neoplasms
1
Precancerous Conditions
1
Polycystic Ovary Syndrome
1
Overall Survival
1
Neoplastic Cells, Circulating
1
Nasopharyngeal Carcinoma
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Prolymphocytic
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Kidney Neoplasms
1
Interventions
epigallocatechin gallate
2
XENP 1595
2
Etanercept
2
Ascorbic Acid
2
salicylsalicylic acid
1
microcrystalline cellulose
1
ginger extract
1
dapagliflozin
1
cytisine
1
Tablets
1
Sulindac
1
Spirometry
1
Specimen Handling
1
Sodium Salicylate
1
Radiotherapy, Conformal
1
Pregabalin
1
Omeprazole
1
Losartan
1
Ketorolac
1
Interleukin 1 Receptor Antagonist Protein
1
Infliximab
1
Hematologic Tests
1
Diet Therapy
1
Atorvastatin
1
Aspirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Inflammation
×
Atorvastatin
×
Clear all
NCT01821404
2018-05-07
ESTO1
Tampere University Hospital
Phase 2
Completed
160 enrolled